Novo Holdings Annual Report 2020 Here

Total Page:16

File Type:pdf, Size:1020Kb

Novo Holdings Annual Report 2020 Here Novo Holdings A/S Annual Report 2020 1 annual report Novo Holdings A/S Tuborg Havnevej 19 2900 Hellerup, Denmark CVR 24257630 2 Novo Holdings A/S Annual Report 2020 Content Management review 06 Letter from the Chairman and the CEO Introducing 08 Novo Holdings at a glance Novo Holdings 10 Our business model 4 12 2020 performance highlights 16 Purpose and ambition 18 People and organisation Our business 20 Investment strategy 14 34 Financial performance 2020 and outlook for 2021 38 Business and financial risk 44 Corporate governance Governance 45 Boards and Leadership Team 42 50 Responsible investments Novo Holdings A/S Annual Report 2020 3 Statements 54 Statement of comprehensive income 55 Balance sheet Financial statements 56 Equity statement 52 57 Cash flow statement 59 Notes to the financial statement Management's 84 Management’s statement statement and 82 Auditor’s report 85 Independent Auditor’s report Front page: Novo Holdings is a world-leading life science investor with a focus on creating long-term value. We invest in life science companies at all stages of development and in a broad portfolio of equity and fixed income securities. 4 Novo Holdings A/S Annual Report 2020 Management review Introducing Novo Holdings Novo Holdings has a substantial portfolio of industrial biotech companies providing sustainable solutions within areas including agriculture and food production. 6 Novo Holdings A/S Annual Report 2020 Letter from the Chairman and the CEO The year 2020 was marked by the significant challenges brought about by the companies, taking its total portfolio to 10 companies. In just two years, coronavirus pandemic. Despite that, our organization demonstrated adaptability Novo Growth has emerged as a leading life science growth equity investor and resilience, and our teams delivered very satisfactory financial results. and has a portfolio of companies in sectors ranging from bioindustrials to diagnostics to gene therapy. Novo Holdings realized record Income and Investment Returns of DKK 29 billion in 2020, up from DKK 26 billion in 2019. This result is well balanced and Novo Seeds invested DKK 582 million in 2020 including investments into based on a strong performance from both the Novo Group companies and eight new companies. A key highlight of the year was the NASDAQ IPO of from the Investment Portfolio, with the latter generating a very satisfactory Galecto at a valuation of around USD 400 million. Copenhagen-based Galecto return of 12% for the year, which is significantly ahead of benchmark. Novo was seeded by Novo Seeds in 2011 with an investment of DKK 2 million. Holdings closed the year with a record DKK 457 billion in total assets, up from DKK 411 billion in 2019, with the Investment Portfolio alone increasing to a Our non-life science investment team, Novo Capital Investors, closed the year record DKK 150 billion, up from DKK 127 billion in 2019. with DKK 73 billion of assets under management and generated a return of 8%, well ahead of benchmark. Key highlights of the year include investments Novo Holdings is a long-term investor with the Investment Portfolio by our new Real Assets team, including a commitment of more than DKK 1 comprising Life Science Investments (52% of the portfolio) and Capital billion in the Nordic real estate group NREP and a commitment of around Investments (48% of the portfolio). As at year-end 2020, the Life Science DKK 1 billion in US-based infrastructure fund I Squared Capital. Investment Portfolio generated a 10-year average return of 17%, while the Capital Investments Portfolio generated a 10-year average return of 9%. The total Novo Holdings Investment Portfolio 10-year average return stands at 12%, and we are pleased to be delivering on our key objective of generating attractive long-term returns on the assets of the Novo Nordisk Foundation. In addition to a very satisfactory financial performance, Novo Holdings attained important strategic milestones in 2020 as well as notable accomplishments with societal impact. Financial highlights Principal Investments deployed DKK 5 billion of capital, including the private investment into WCG and two sizeable public investments into a leading MedTech and a leading pharma services company, all US-based. In Europe, we added to our position in German-based Evotec. Novo Ventures witnessed an unprecedented level of activity and invested a record DKK 3.7 billion, cementing its position as a leading global life science venture investor. Novo Ventures executed 79 investments in 2020 and among its exits were 9 IPOs. Our newest team, Novo Growth, invested DKK 1.1 billion in four Novo Holdings A/S Annual Report 2020 7 Strategic highlights Action Fund to invest in AMR projects. In addition to our work with the 2020 was an important year for the geographical expansion of our Life IFPMA, Novo Holdings invested USD 50 million on behalf of the Novo Science Investment teams. We expanded into Asia with the opening of Nordisk Foundation, and Novo Nordisk separately invested 25 million our Singapore office, and we established a presence in the US for Principal into the fund. The Action Fund is the largest and most comprehensive Investments, with the recruitment of two senior partners. commitment ever made to tackle the AMR crisis. On the asset class front, 2020 was a milestone year from a diversification We continued our deliberate focus on active investments in the perspective. Most of the asset class expansion took place in Novo Capital bioindustrial segment, to deliver sustainable solutions to the industry. Investors, where we established a Real Assets team, a Technology Venture Our bioindustrial investments in 2020 stand at DKK 337 million, with an Capital team and a Credit team. exposure of total assets of DKK 1.3 billion by end 2020. Further, we continued to grow the Novo Advisory Group, which assists us The Novo Holdings ethos is expressed by the Novo Holdings Way, and its in our life science investment decisions. In 2020, we welcomed Britt Melby cornerstones are Performance, Respect and Responsibility. Our teams lived up Jensen, Per Lofberg and Peder Holk Nielsen to the group. to this ethos in an exemplary manner in 2020 by delivering a very satisfactory performance under the extremely challenging circumstances created by Societal impact highlights the COVID-19 crisis. We would like to express our deep gratitude to all our Novo Holdings’ deliberate life sciences focus places us in a very colleagues for their commitment and resilience during this very challenging year. special position as a long-term investor with a positive societal impact. 2020 was a very special year for our efforts in tackling the anti-microbial resistance (AMR) crisis. Aside from our REPAIR Impact Fund representing accumulated investments of DKK 407 million into nine companies by the end of 2020, we worked closely with the IFPMA (International Federation Lars Rebien Sørensen Kasim Kutay of Pharmaceutical Manufacturers) on the formation of the USD 1 billion Chairman of the Board Chief Executive Officer Strategic objectives Strong owner of Novo Nordisk Generate attractive returns Promote better health, sustainability and Novozymes and welfare • Secure a set, minimum level of ownership • Deliver long-term attractive returns • Invest in and build the Nordic biotech industry • Ensure a set liquidity reserve to provide • Provide excess returns to set benchmarks • Make life science investments that improve financial support if ever required people's lives and support biosustainability • Manage Impact Investments 8 Novo Holdings A/S Annual Report 2020 Novo Holdings at a glance DKK 134 bn 109 457(EUR 61 bn) Global employees Portfolio companies Total investment assets 5 * offices *The offices in US, UK and Asia are separate entities that provide certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying and analysing various investment opportunities among life sciences companies in the US, UK and Asia as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts. Novo Holdings A/S Annual Report 2020 9 DKK % bn 9 150(EUR 20 bn) Total 5-year average return Investment Portfolio of DKK on the Investment Portfolio DKK bn 10(EUR 1 bn) % Deployed into life sciences Return17 on Life Science Investments Total Income and Return % Return on 8Capital Investments DKK29 bn(EUR 4 bn) 10 Novo Holdings A/S Annual Report 2020 Our business model Novo Holdings is a holding and investment company, wholly owned by the Novo Nordisk Foundation. Our objective is to meet the Novo Nordisk Foundation’s strategic and commercial goals, which requires us to make Dividends to the investments with a view to long-term returns. Novo Nordisk Foundation 414 Education & outreach Deep life science expertise Novo Life Science Investors 585 Patient-centred and 446 Cash inflow from dividends research-based care Innovation and share-buy back programmes of Novo Nordisk and Novozymes DKK 5540 n Payouts and grants awarded in 2020 by the 324 Novo Nordisk Foundation Social, humanitarian 1908 and development aid Biomedical and Proven capital investment health science track-record Novo Capital Investors research and applications Return from Investment Portfolio 1346 517 Life science research and industrial Natural and technical science applications promoting sustainability research and interdisciplinarity Novo Group Novo Holdings Novo Nordisk Foundation Novo Holdings A/S Annual Report 2020 11 Dividends to the Novo Nordisk Foundation 414 Education
Recommended publications
  • Quarterly Report
    Initiation of stock buyback program On February 8, 2021, Novozymes will initiate a stock buyback program as announced in Company February 8, 2021 Announcement No. 1, of February 2, 2021. Under the program Novozymes will buy back B shares Company announcement No. 05 worth up to DKK 1.5 billion in total during the remainder of 2021, corresponding to around 4.1 million B shares at the current share price. The program is contingent upon no major strategic initiatives being decided upon that will require a significant amount of capital, for example a major acquisition. Contact information The stock acquired within the program will be used to reduce the common stock and to meet [email protected] obligations arising from stock-based incentive programs. The cancelation of stock will take place after the program is finished and will be subject to approval at the Annual Shareholders’ Meeting. Tobias Cornelius Björklund +45 3077 8682 [email protected] Novozymes’ majority shareholder, Novo Holdings A/S, a holding company wholly owned by the Novo Nordisk Foundation, has informed Novozymes that it intends to consider its participation in Carl Ahlgren Novozymes' stock buy-back program on a year-by-year basis and that, for 2021, it plans to +1 919 702 6144 [email protected] participate in the program. Novo Holdings A/S intends to reduce its holding of B shares so that it will continue to hold around 25.5% of the total shares. Ulrik Wu Svare +45 3077 3187 The maximum number of shares to be purchased by the company per daily market session will be [email protected] equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days.
    [Show full text]
  • TOBAM Voting Report Meeting for GCL-POLY ENERGY HOLDINGS LTD
    TOBAM Voting report Votes Meeting for GCL-POLY ENERGY HOLDINGS LTD on 05 Jan 2018 Management ISS recommandation recommandation TOBAM Vote 1 Approve Wafer Products Supply Framework Agreement, Annual Cap and Related Transactions For For For Votes Available Voted MDP - TOBAM Anti-Benchmark All Countries World 10.00 10.00 1 TOBAM Voting report Votes Meeting for AIRASIA BHD on 08 Jan 2018 Management ISS recommandation recommandation TOBAM Vote 1 Approve Internal Reorganization For For For 1 Approve Internal Reorganization For For For Votes Available Voted MDP - TOBAM Anti-Benchmark Emerging Markets 12,860,200.00 12,860,200.00 2 TOBAM Voting report Votes Meeting for AIRASIA BHD on 08 Jan 2018 Management ISS recommandation recommandation TOBAM Vote Court-Ordered Meeting for Shareholders 1 Approve Scheme of Arrangement For For For Court-Ordered Meeting for Shareholders 1 Approve Scheme of Arrangement For For For Votes Available Voted MDP - TOBAM Anti-Benchmark All Countries World 121,700.00 121,700.00 3 TOBAM Voting report Votes Meeting for ZODIAC SA on 09 Jan 2018 Management ISS recommandation recommandation TOBAM Vote Ordinary Business 1 Approve Financial Statements and Statutory Reports For For For 2 Approve Consolidated Financial Statements and Statutory Reports For For For 3 Approve Allocation of Income and Absence of Dividends For For For 4 Acknowledge Auditors' Special Report on Related-Party Transactions Mentioning the Absence of For For For 5 Authorize Repurchase of Up to 10 Percent of Issued Share Capital For For For 6 Reelect Patrick
    [Show full text]
  • COVID-19 Initiatives in 2020 1
    Novo Nordisk Foundation - COVID-19 initiatives in 2020 1 COVID-19 initiatives in 2020 The Novo Nordisk Foundation’s response to the coronavirus pandemic Grants have been awarded in the areas of scientific research, education and outreach, patient care, diagnostics as well as for social and humanitarian efforts. Establishment of TestCenter Research into the long-term health Danmark: consequences of COVID-19 illness: DKK 250m DKK 40,0m (for distribution in 2021) Emergency production of ethanol: Humanitarian grants: DKK 8,75m DKK 37,4m Emergency grants for COVID-19 Educational support for vulnerable projects in the Danish Realm: children after the lockdown: DKK 84,5m DKK 4,7m Grants for other COVID-19 research: Total amount: DKK 34,8m DKK 460,15m Read more about the Novo Nordisk Foundation’s efforts at: novonordiskfonden.dk/en/about-the-foundation/initiatives-covid-19/ Novo Nordisk Foundation - COVID-19 initiatives in 2020 3 An extraordinary situation calls for collaboration With the coronavirus pandemic, Denmark was plunged into a of our Board of Directors and employees. I am happy to see that health crisis as well as an economic crisis that required – and many of the projects we have supported have benefited people continues to require – an extraordinary effort from the whole of and society. You can read more about them at the Foundation’s society. The crisis is not over yet, but with vaccines on the way, homepage and at sciencenews.dk. there is light at the end of the tunnel, and hopefully we can begin to see a return to normal life in the course of 2021.
    [Show full text]
  • Improving the Lives of the People We Touch
    Improving the lives of the people we touch ConvaTec Group Plc Annual Report and Accounts 2018 2018 highlights Financial highlights1 Revenue Operating profit Earnings per share $1,832m +3.8% $268m +8.0% $0.11 +37.5% ,m m . ,m m . Adjusted EBIT2 Adjusted EBIT margin Adjusted earnings per share $429m -6.0% 23.4.% $0.16 m . . m . . 1. Certain financial measures in this Annual Report and Accounts, including adjusted performance measures above, are not prepared in accordance with IFRS. All adjusted performance measures are reconciled to the most directly comparable measure prepared in accordance with IFRS on pages 66 to 71. 2. Adjusted EBIT is equivalent to adjusted operating profit as reconciled on pages 68 to 69. Contents Overview Governance Financial statements Other information IFC Financial highlights and 72 Governance report at 124 Independent auditor’s 180 Shareholder information contents a glance report to the members 01 Introduction 73 Chairman’s governance of ConvaTec Group Plc 02 Our business at a glance letter 133 Consolidated Statement 04 Our investment case 74 Governance in action of Profit or Loss 75 Board statements and how 134 Consolidated Statement Strategic report we have applied the Code of Comprehensive Income 05 Strategic report overview 78 Leadership 135 Consolidated Statement 06 Chairman’s letter 80 Board of Directors of Financial Position 08 Chief Executive Officer’s 84 Effectiveness 136 Consolidated Statement review 86 Nomination Committee of Changes in Equity 12 Our market environment report 137 Consolidated
    [Show full text]
  • Proxy Vote Record
    Company Name Ticker Country Meeting Date Proposal Text Vote Instruction A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Receive Report of Board A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Accept Financial Statements and Statutory Reports For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve Discharge of Management and Board For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve Allocation of Income and Dividends of DKK 150 Per Share For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Jim Hagemann Snabe as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Ane Maersk Mc-Kinney Uggla as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Robert Maersk Uggla as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Jacob Andersen Sterling as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Reelect Thomas Lindegaard Madsen as Director For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Ratify PricewaterhouseCoopers as Auditors For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Authorize Board to Declare Extraordinary Dividend For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve DKK 784.9 Million Reduction in Share Capital via Share Cancellation For A.P. Moller-Maersk A/S MAERSK.B Denmark 23-Mar-20 Approve Guidelines for Incentive-Based Compensation for Executive Management and Board Against A.P.
    [Show full text]
  • Meeting Details Report
    Company Name Country Meeting Date Proposal Text Vote Instruction A.D.O. Group Ltd. Israel 01-Mar-18 Elect Doron Haim Cohen as External Director For A.D.O. Group Ltd. Israel 01-Mar-18 Elect Riki Granot as External Director For A.D.O. Group Ltd. Israel 01-Mar-18 Elect Alex Hefetz as External Director Do Not Vote A.D.O. Group Ltd. Israel 01-Mar-18 Elect Barak Salomon as External Director Do Not Vote A.D.O. Group Ltd. Israel 01-Mar-18 Vote FOR if you are a controlling shareholder or have a personal interest in one or several resolutions, as indicated in the proxy card; otherwise, vote AGAINST. You Against may not abstain. If you vote FOR, please provide an explanation to your account manager A.D.O. Group Ltd. Israel 01-Mar-18 If you are an Interest Holder as defined in Section 1 of the Securities Law, 1968, vote FOR. Otherwise, vote against. Against A.D.O. Group Ltd. Israel 01-Mar-18 If you are a Senior Officer as defined in Section 37(D) of the Securities Law, 1968, vote FOR. Otherwise, vote against. Against A.D.O. Group Ltd. Israel 01-Mar-18 If you are an Institutional Investor as defined in Regulation 1 of the Supervision Financial Services Regulations 2009 or a Manager of a Joint Investment Trust Fund as For defined in the Joint Investment Trust Law, 1994, vote FOR. Otherwise, vote against. AmerisourceBergen Corporation USA 01-Mar-18 Elect Director Ornella Barra Against AmerisourceBergen Corporation USA 01-Mar-18 Elect Director Steven H.
    [Show full text]
  • Thenovo Nordiskprize
    Professor 2020 Preben Bo Mortensen The Novo Nordisk Prize THE NOVO NORDISK PRIZE 2020 Nomination of Preben Bo Mortensen The Novo Nordisk Foundation is awarding the 2020 Novo Nordisk Prize to Professor Preben Bo Mortensen for his remarkable pioneering registry-based studies combining data from biobanks and population registries demonstrating key causes for developing severe mental disorders and for the impact this research has had on medical science. Preben Bo Mortensen graduated as a medical doctor from Aarhus Throughout his career, Preben Bo Mortensen has contributed in University in 1986 and did clinical training in psychiatry and particular to understanding important causes for schizophrenia neurology. Since 2000, he has been a professor at Aarhus University and other mental disorders, including both environmental and and headed the National Centre for Register-based Research at genetic causes, course of the disorders, comorbidities and mortality. Aarhus University. Professor Preben Bo Mortensen has provided In addition, Preben Bo Mortensen has contributed exceptionally an internationally outstanding and exceptional contribution to to understanding the causes of suicide, which exemplifies highly understanding the epidemiology of mental disorders, which are very original scientific contributions, and in 1997 he became member frequent disorders and often with a serious clinical course. He began of the task group on suicide mortality under Denmark’s Ministry of his scientific career already as a medical student and was awarded Health. In parallel with his outstanding scientific career, Preben Bo Aarhus University’s gold medal for his research on relationships Mortensen has had multiple positions of trust. He has collaborated linking cancer with schizophrenia.
    [Show full text]
  • Steno Diabetes Centres – a Danish Public Private Partnership Page PUBLIC VERSUS PRIVATE FUNDING in DENMARK
    Jannik Hilsted, M.D., D.M.Sc. June 18th, 2020 Chief Medical Officer Steno Diabetes Centres – a Danish Public Private Partnership Page PUBLIC VERSUS PRIVATE FUNDING IN DENMARK > Population 5.7 million > Healthcare >85% funded by public sources > Free and equal access to healthcare Page IT ALL BEGAN WITH INSULIN The clinician The investor Hans Christian Hagedorn August Kongsted The entrepreneurs The scientists Thorvald Pedersen Harald Pedersen Marie Krogh August Krogh Page Page Page STENO DIABETES CENTER 1932–2016 • Merger of Steno Memorial Hospital and Hvidøre Hospital, 1991 • Complex ownership (Novo Nordisk A/S, Novo Nordisk Foundation and Capital Region of Denmark) • From manufacturer-driven test institution to independent healthcare provider • Decentralization and declining number of patients Page STENO DIABETES CENTERS A NATIONWIDE SOLUTION • PageTo create an internationally leading treatment and research environment to benefit everyone with diabetes in Denmark • To contribute to fewer new people with diabetes and longer survival with better quality of life for people with diabetes VISION FOR THE STENO DIABETES CENTERS Page Public–Private Partnerships Denmark’s public healthcare system owns and operates the Steno Diabetes Centers The Foundation grant covers: Supplementary treatment Clinical research Education Health promotion Constructing and equipping the building • The agreement runs 10-12 years (but Novo Nordisk Foundation has no end date for the collaboration) • Financially the Novo Nordisk Foundation supports the Danish regions
    [Show full text]
  • Vote Summary Report
    Vote Summary Report Reporting Period: 01/01/2020 to 03/31/2020 Location(s): Massachusetts Financial Services Dr. Reddy's Laboratories Limited Meeting Date: 01/02/2020 Country: India Primary Security ID: Y21089159 Record Date: 11/15/2019 Meeting Type: Court Ticker: 500124 Primary CUSIP: Y21089159 Primary ISIN: INE089A01023 Primary SEDOL: 6410959 Proposal Vote Number Proposal Text Proponent Mgmt Rec Instruction Court-Ordered Meeting for Shareholders Mgmt 1 Approve Scheme of Amalgamation and Mgmt For For Arrangement Zoomlion Heavy Industry Science & Technology Co. Ltd. Meeting Date: 01/06/2020 Country: China Primary Security ID: Y9895V103 Record Date: 12/27/2019 Meeting Type: Special Ticker: 1157 Primary CUSIP: Y9895V103 Primary ISIN: CNE100000X85 Primary SEDOL: B544N70 Proposal Vote Number Proposal Text Proponent Mgmt Rec Instruction EGM BALLOT FOR HOLDERS OF A SHARES Mgmt 1 Approve Stock Ownership Plan Mgmt For For 2 Approve Adoption of the Management Rules Mgmt For For of the Stock Ownership Plan 3 Authorize Board to Deal With All Matters in Mgmt For For Relation to the Stock Ownership Plan 4 Approve Amendments to Articles of Mgmt For For Association to Expand Business Scope 5 Approve Merger by Absorption and Related Mgmt For For Transactions 6 Approve Provision of a Guarantee by the SH For For Company in Favour of Zoomlion Finance and Leasing (Beijing) Co., Ltd. and Related Transactions 7 Approve Proposed Registration by the SH For For Company for the Issue of Asset-Back Securities and Related Transactions Vote Summary Report Reporting
    [Show full text]
  • Foundation Ownership at Novo Nordisk1
    Foundation Ownership at Novo Nordisk1 Steen Thomsen2 Center for Corporate Governance Copenhagen Business School 4. May 2016 Overview Novo Nordisk is a large Danish life science company specializing in diabetes care. Its financial performance has been good over the past decades - outperforming both the closest rivals Eli Lilly and Sanofi as well as the S&P 500 index. It is now the largest Nordic firm by market value. The company is majority-owned by the Novo Nordisk Foundation through the holding company Novo. This case study considers the causes of the company’s success and to what extent they are related to foundation ownership. The company has apparently benefitted from a long run commitment to diabetes care, strong values, employee loyalty, and strict governance principles which may have contributed to its success along with the special characteristics of insulin production. 1 This paper is part of The Research Project on Industrial Foundations at the Center for Corporate Governance, Copenhagen Business School. I am grateful for interviews with chair of Novo Nordisk, Dr. Goran Ando, vice chair of Novo Nordisk Jeppe Christiansen, former CEO of Novo Nordisk Mads Øvlisen, chair of the Novo Nordisk Foundation and former chair of Novo Nordisk Sten Scheibye. Thanks also for helpful comments by Chief Communications Officer Steffen Lüders and Chief of Staff Thomas Alslev, the Novo Nordisk Foundation. I am grateful to Signe Marie Degn for research assistance. 2 Professor, Center for Corporate Governance, Copenhagen Business School, e-mail [email protected]. 0 Introduction Novo Nordisk is a multinational pharmaceutical company headquartered in Denmark.
    [Show full text]
  • UK and European Equities Voting Summary Report Q1 2021
    FOR PROFESSIONAL CLIENTS/QUALIFIED INVESTORS ONLY – NOT FOR RETAIL USE OR DISTRIBUTION UK and European Equities Voting Summary Report Q1 2021 Table of contents FIRST LETTER OF COMPANY NAME PAGE FIRST LETTER OF COMPANY NAME PAGE # – N 72 A 3 O 79 B 13 P 81 C 21 Q 84 D 32 R 85 E 37 S 88 F 43 T 110 G 47 U 121 H 51 V 124 I 55 W 128 J 58 X – K 62 Y 130 L 65 Z 131 M 67 These voting summary reports represent voting activity for accounts managed by Portfolio Managers in London of J.P. Morgan Asset Management (UK) Ltd. Information regarding proxy voting activity is available for JPMAM accounts, where securities are held in the accounts. Please contact your client account manager/client advisor for any further inquiries related to proxy voting in your account. 2 | UK AND EUROPEAN EQUITIES – VOTING SUMMARY REPORT BACK TO CONTENTS Meeting Record Meeting Proposal Management Vote Company Name Date Date Type Proponent Number Proposal Text Recommendation Instruction A.P. Moller-Maersk A/S 23-Mar-21 16-Mar-21 Annual Management 1 Receive Report of Board A.P. Moller-Maersk A/S 23-Mar-21 16-Mar-21 Annual Management 2 Accept Financial Statements and Statutory Reports For For A.P. Moller-Maersk A/S 23-Mar-21 16-Mar-21 Annual Management 3 Approve Discharge of Management and Board For For A.P. Moller-Maersk A/S 23-Mar-21 16-Mar-21 Annual Management 4 Approve Allocation of Income and Dividends of DKK 330 Per Share For For A.P.
    [Show full text]
  • Notice for the Annual General Meeting of Novo Nordisk A/S
    Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 22 February 2019 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2019 at 2.00 pm (CET) at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark. The notice for the Annual General Meeting is attached. BOARD OF DIRECTORS – PROPOSED CHANGES IN COMPOSITION All current board members elected by the Annual General Meeting in 2018 are up for election. The Board of Directors proposes re-election of all current board members elected by the Annual General Meeting: Helge Lund (chairman) Jeppe Christiansen (vice chairman), Brian Daniels, Andreas Fibig, Sylvie Grégoire, Liz Hewitt, Kasim Kutay and Martin Mackay. The Board of Directors proposes election of Laurence Debroux at the Annual General Meeting. Laurence Debroux is Group Chief Financial Officer and member of the Executive Board of Heineken N.V., the Netherlands. The Board of Directors recommends election of Laurence Debroux primarily because of her significant experience with financial and accounting practices, extensive global experience within the pharmaceutical industry and experience from executive positions in major international companies. Novo Nordisk A/S Novo Allé Telephone: Internet: Investor Relations 2880 Bagsværd +45 4444 8888 www.novonordisk.com Denmark CVR no: 24 25 67 90 Company announcement No 12 / 2019 Page 2 of 2 Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
    [Show full text]